Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 164Carboplatin 136Cisplatin 84Paclitaxel 80Gemcitabine 77Pemetrexed 74Bevacizumab 65Docetaxel 54Fluorouracil 50Oxaliplatin 48Dexamethasone 45durvalumab 42atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Nivolumab 35Cetuximab 35Rituximab 33Cyclophosphamide 33Injections 31Fulvestrant 30venetoclax 28Prednisone 28Lenalidomide 27enzalutamide 26Irinotecan 25pomalidomide 24Letrozole 24daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cytochrome P-450 CYP2C19 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡